Advertisement
NEW YORK (AP) — Boehringer Ingelheim Pharmaceuticals Inc. and Pfizer Inc. said Thursday the Food and Drug Administration approved Spiriva HandiHaler as a treatment for reducing symptoms and difficulty breathing because of chronic obstructive pulmonary disease. The inhalable drug is already approved as a once-daily maintenance treatment for breathing problems associated with the condition, also called COPD, which includes chronic bronchitis and emphysema. Symptoms associated with the condition include wheezing and difficulty breathing.
Advertisement
Advertisement